Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI - PubMed
5 hours ago
- #MRI Biomarkers
- #Immunotherapy
- #Hepatocellular Carcinoma
- Prospective study on atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (HCC) using Gd-EOB-DTPA-MRI.
- Hepatobiliary phase hyperintensity on MRI reflects Wnt/β-catenin signaling, previously linked to poor immune monotherapy response.
- 152 patients with Child-Pugh class A liver function enrolled across 12 Japanese centers.
- 37.5% of patients had hyperintense nodules (relative enhancement ratio ≥ 0.9).
- Hyperintense group showed higher objective response rate (36.8% vs. 22.1%) and comparable progression-free and overall survival.
- Time to partial response was significantly shorter in the hyperintense group (26.0 months vs. not reached, p = 0.033).
- Findings suggest hyperintensity does not indicate resistance to combination immunotherapy.
- Supports use of atezolizumab plus bevacizumab in 'immune-cold' HCC with Wnt/β-catenin activation.